Medical devices, healthcare technology and the business of care
PMA approval · P020056

NATRELLE SILICONE-FILLED BREAST IMPLANTS

Allergan · Decision date Nov 17, 2006

MEDTECHLEDGER EXPLANATIONP020056

What did the FDA approve?

FDA approval P020056, dated November 17, 2006, covers the Inamed silicone-filled breast implants, now listed under applicant Allergan. The decision statement describes the device as indicated for breast augmentation in women at least 22 years old and for breast reconstruction in women of any age. Augmentation is defined to include primary surgery to increase breast size and revision surgery to correct or improve a primary augmentation result.

Reconstruction is defined to include primary replacement of breast tissue removed due to cancer or trauma or that failed to develop properly due to a severe breast abnormality, plus revision surgery to correct or improve a primary reconstruction result. The statement reports the approved scope and purpose; it does not itself provide independent proof of safety or clinical effectiveness. No supplement type or reason is supplied, so no relationship to a prior PMA can be established from these fields.

FDA approval order statement

APPROVAL FOR THE INAMED SILICONE-FILLED BREAST IMPLANTS. THIS DEVICE IS INDICATED FOR BREAST AUGMENTATION FOR WOMEN AT LEAST 22 YEARS OLD AND FOR BREAST RECONSTRUCTION FOR WOMEN OF ANY AGE. BREAST AUGMENTATION INCLUDES PRIMARY BREAST AUGMENTATION TO INCREASE THE BREAST SIZE, AS WELL AS REVISION SURGERY TO CORRECT OR IMPROVE THE RESULT OF A PRIMARY BREAST AUGMENTATION SURGERY. BREAST RECONSTRUCTION INCLUDES PRIMARY RECONSTRUCTION TO REPLACE BREAST TISSUE THAT HAS BEEN REMOVED DUE TO CANCER OR TRAUMA OR THAT HAS FAILED TO DEVELOP PROPERLY DUE TO A SEVERE BREAST ABNORMALITY. BREAST RECONSTRUCTION ALSO INCLUDES REVISION SURGERY TO CORRECT OR IMPROVE THE RESULT OF A PRIMARY BREAST RECONSTRUCTION SURGERY.
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Nov 17, 2006

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P020056
Regulatory pathway
Premarket approval application
Applicant
Allergan
Product code
FTR
Decision code
APPR
Decision date
Nov 17, 2006
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, breast, noninflatable, internal, silicone gel-filled.

Applicant
Allergan
Product code
FTR
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P020056 received

    Application receipt date recorded by FDA.

  2. P020056 · FDA decision

    APPR

  3. P020056/S064 · Related supplement

    Natrelle Silicone-Filled Breast Implants and Natrelle INSPIRA Silicone-Filled Breast Implants

Timeline entries are records held by MedtechLedger for P020056. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P020056

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementSep 29, 2026FDA

Explore the linked device profile

Other records with product code FTR

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Allergan

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2525 Dupont Dr., Irvine, CA, 92612

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records